NCT00658580View on ClinicalTrials.gov

Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

361

Participants

Timeline

Start Date

April 30, 2000

Primary Completion Date

December 31, 2013

Study Completion Date

February 28, 2015

Conditions
Small Cell Lung Carcinoma, Extensive Disease
Interventions
DRUG

Cisplatin + etoposide

"Cisplatin 90 mg/m² day 1, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks"

DRUG

Epirubicin + ifosfamide + etoposide

"Epirubicin 60 mg/m² day 1, every 3 weeks~Ifosfamide (+ uromitexan) 1.5 g/m² days 1-3, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks"

Trial Locations (4)

1000

Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet, Brussels

Unknown

Department of Pneumology CHRU Lille, Lille

Hellenic Cancer Institute - St Savas Oncology Hospital, Athens

Medical Oncology Hospital de Sagunto, Valencia

All Listed Sponsors
lead

European Lung Cancer Working Party

OTHER

NCT00658580 - Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer | Biotech Hunter | Biotech Hunter